Ovarian Cancer Specialty Channel

FDA Approval

FDA Accepts New Drug Application for Relacorilant as a Treatment for Patients With Platinum-Resistant Ovarian Cancer

09/10/2025

Allison Casey

The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.

The FDA has accepted an NDA for...

09/10/2025

Oncology

News

Alpelisib Plus Olaparib Fails to Improve Outcomes For Platinum-Resistant/Platinum-Refractory High-Grade Serous Ovarian Cancer

08/19/2025

Stephanie Holland

According to primary analysis results from the phase 3 EPIK-O/ENGOT-ov61 trial, alpelisib plus olaparib did not improve outcomes among previously treated patients with platinum-resistant or platinum-refractory high-grade serous ovarian cancer...

According to primary analysis...

08/19/2025

Oncology

FDA Approval

FDA Approves Avutometinib Plus Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

05/08/2025

Stephanie Holland

Based on results from the RAMP-201 trial, the FDA has approved avutometinib plus defactinib for previously treated patients with KRAS-mutated recurrent low-grade serous ovarian cancer.

Based on results from the...

05/08/2025

Oncology

News

TTFields Plus Paclitaxel Fails to Improve Survival Among Pretreated Patients With Platinum-Resistant Ovarian Cancer

04/29/2025

Stephanie Holland

According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.

According to results from the...

04/29/2025

Oncology

News

Relacorilant Plus Nab-Paclitaxel Improves PFS for Patients With Platinum-Resistant Ovarian Cancer

04/04/2025

Stephanie Holland

Results from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel improved survival among patients with platinum-resistant ovarian cancer.

Results from the phase 3 ROSELLA...

04/04/2025

Oncology

Conference Coverage

Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers

09/12/2024

Allison Casey

According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.

According to results of the...

09/12/2024

Oncology

FDA Approval

FDA Approves New Formulation of Thiotepa for Patients With Breast and Ovarian Cancer

07/01/2024

Stephanie Holland

The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.

The FDA has approved the new...

07/01/2024

Oncology

News

Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer

06/18/2024

Allison Casey

According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...

According to results from the...

06/18/2024

Oncology

Conference Coverage

Batiraxcept Plus Paclitaxel for Patients With Platinum-Resistant Ovarian Cancer

06/13/2024

Allison Casey

According to phase 2 results, batiraxcept plus paclitaxel did not improve the survival outcomes among the overall cohort of patients with platinum-resistant ovarian cancer, but may benefit patients with AXL-high expression.

According to phase 2 results,...

06/13/2024

Oncology

Conference Coverage

Suvemcitug Plus Chemotherapy Improved Survival Outcomes Among Patients With Platinum-Resistant Ovarian Cancer

06/13/2024

Allison Casey

Results from the phase 3 SCORES trial found suvemcitug plus chemotherapy improved the progression-free survival, objective response rate, and disease control rate among patients with platinum-resistant ovarian cancer.

Results from the phase 3 SCORES...

06/13/2024

Oncology

Conference Coverage

Olaparib Alone As a Chemotherapy-Free Approach Post-Cytoreduction for Patients With Platinum-Sensitive High-Grade Serous Ovarian Cancer

06/03/2024

Allison Casey

According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...

According to phase 2 data to be...

06/03/2024

Oncology

News

FDA Approval

FDA Accepts New Drug Application for Relacorilant as a Treatment for Patients With Platinum-Resistant Ovarian Cancer

09/10/2025

Allison Casey

The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.

The FDA has accepted an NDA for...

09/10/2025

Oncology

News

Alpelisib Plus Olaparib Fails to Improve Outcomes For Platinum-Resistant/Platinum-Refractory High-Grade Serous Ovarian Cancer

08/19/2025

Stephanie Holland

According to primary analysis...

08/19/2025

Oncology

FDA Approval

FDA Approves Avutometinib Plus Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

05/08/2025

Stephanie Holland

Based on results from the RAMP-201 trial, the FDA has approved avutometinib plus defactinib for previously treated patients with KRAS-mutated recurrent low-grade serous ovarian cancer.

Based on results from the...

05/08/2025

Oncology

News

TTFields Plus Paclitaxel Fails to Improve Survival Among Pretreated Patients With Platinum-Resistant Ovarian Cancer

04/29/2025

Stephanie Holland

According to results from the...

04/29/2025

Oncology

News

Relacorilant Plus Nab-Paclitaxel Improves PFS for Patients With Platinum-Resistant Ovarian Cancer

04/04/2025

Stephanie Holland

Results from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel improved survival among patients with platinum-resistant ovarian cancer.

Results from the phase 3 ROSELLA...

04/04/2025

Oncology

Conference Coverage

Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers

09/12/2024

Allison Casey

According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.

According to results of the...

09/12/2024

Oncology

FDA Approval

FDA Approves New Formulation of Thiotepa for Patients With Breast and Ovarian Cancer

07/01/2024

Stephanie Holland

The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.

The FDA has approved the new...

07/01/2024

Oncology

News

Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer

06/18/2024

Allison Casey

According to results from the...

06/18/2024

Oncology

Conference Coverage

Batiraxcept Plus Paclitaxel for Patients With Platinum-Resistant Ovarian Cancer

06/13/2024

Allison Casey

According to phase 2 results,...

06/13/2024

Oncology

Conference Coverage

Suvemcitug Plus Chemotherapy Improved Survival Outcomes Among Patients With Platinum-Resistant Ovarian Cancer

06/13/2024

Allison Casey

Results from the phase 3 SCORES...

06/13/2024

Oncology

Interactive Features

Quiz

Front-Line Treatment Options for Ovarian Cancer

12/20/2023

Oncology

Quiz

New and Emerging Targeted Therapies for Relapsing Ovarian Cancer

11/29/2023

Oncology

Quiz

Maintenance Olaparib Rechallenge for Ovarian Cancer

10/31/2023

Oncology

Quiz

Sleeping Beauty Mutagenesis in High-Grade Ovarian Cancer

05/16/2023

How is Sleeping Beauty mutagenesis used to research tumor progression and potentially develop targeted therapies for future treatments for high-grade ovarian cancer?

How is Sleeping Beauty...

05/16/2023

Oncology

Quiz

Quiz: FDA Approves Mirvetuximab Soravtansine

12/15/2022

What treatment must patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer have received prior to receiving mirvetuximab soravtansine?

What treatment must patients...

12/15/2022

Oncology

Quiz

Quiz: Hyperthermic Intraperitoneal Chemotherapy Agent of Choice

12/02/2022

What is the most prevalent chemotherapy option when providing HIPEC to patients with ovarian cancer?

What is the most prevalent...

12/02/2022

Oncology

Quiz

Quiz: Pafolacianine With Near-Infrared Imaging for Detecting Folate Receptor-Positive Ovarian Cancer

11/03/2022

A phase 3 open-label study found that a single infusion of pafolacianine with near-infrared imaging detected the presence of folate-positive ovarian cancer not detected by white light assessment and palpation in what percentage of patients?

A phase 3 open-label study found...

11/03/2022

Oncology

Quiz

Quiz: Promising Novel Therapy in Tough-to-Treat Ovarian Cancer

03/27/2022

True or false: Researchers at the SGO 2022 Meeting From report mirvetuximab soravtansine monotherapy demonstrated anti-tumor activity in previously treated patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer.

True or false: Researchers at...

03/27/2022

Oncology

Test Your Knowledge

Quiz: A Common Thread in Rising Endometrial Cases in US Women

05/29/2021

Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?

Quiz: Among young adult women in...

05/29/2021

Oncology

Test Your Knowledge

Quiz: Is Intensive Follow-Up of Patients Treated for Endometrial Cancer Beneficial?

05/28/2021

True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.

True or False: Study findings...

05/28/2021

Oncology

Recent News

FDA Approval

FDA Accepts New Drug Application for Relacorilant as a Treatment for Patients With Platinum-Resistant Ovarian Cancer

09/10/2025

Allison Casey

The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.

The FDA has accepted an NDA for...

09/10/2025

Oncology

News

Alpelisib Plus Olaparib Fails to Improve Outcomes For Platinum-Resistant/Platinum-Refractory High-Grade Serous Ovarian Cancer

08/19/2025

Stephanie Holland

According to primary analysis...

08/19/2025

Oncology

FDA Approval

FDA Approves Avutometinib Plus Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

05/08/2025

Stephanie Holland

Based on results from the RAMP-201 trial, the FDA has approved avutometinib plus defactinib for previously treated patients with KRAS-mutated recurrent low-grade serous ovarian cancer.

Based on results from the...

05/08/2025

Oncology

News

TTFields Plus Paclitaxel Fails to Improve Survival Among Pretreated Patients With Platinum-Resistant Ovarian Cancer

04/29/2025

Stephanie Holland

According to results from the...

04/29/2025

Oncology

News

Relacorilant Plus Nab-Paclitaxel Improves PFS for Patients With Platinum-Resistant Ovarian Cancer

04/04/2025

Stephanie Holland

Results from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel improved survival among patients with platinum-resistant ovarian cancer.

Results from the phase 3 ROSELLA...

04/04/2025

Oncology

Conference Coverage

Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers

09/12/2024

Allison Casey

According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.

According to results of the...

09/12/2024

Oncology

FDA Approval

FDA Approves New Formulation of Thiotepa for Patients With Breast and Ovarian Cancer

07/01/2024

Stephanie Holland

The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.

The FDA has approved the new...

07/01/2024

Oncology

News

Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer

06/18/2024

Allison Casey

According to results from the...

06/18/2024

Oncology

News

Trabectedin Did Not Improve Survival or Safety Among Patients With Recurrent Ovarian Cancer and BRCA-Mutation/BRCAness Phenotype

02/09/2024

Stephanie Holland

Results from the phase 3 MITO-23 study demonstrated trabectedin did not improve overall survival and showed a worse safety profile compared to standard chemotherapy among patients with recurrent ovarian cancer and BRCA-mutation/BRCAness...

Results from the phase 3 MITO-23...

02/09/2024

Oncology

News

Mirvetuximab Soravtansine Improved Survival, Response Among Patients With Platinum-Resistant, FRα-Positive Ovarian Cancer

12/19/2023

Stephanie Holland

According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...

According to results from the...

12/19/2023

Oncology

News

Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL

09/26/2025

Emily Estrada

The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.

The implementation of R-ICE...

09/26/2025

Oncology

News

PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL

09/26/2025

Emily Estrada

Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.

Treatment of R/R diffuse large...

09/26/2025

Oncology

News

Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies

09/26/2025

Emily Estrada

Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Compared with traditional...

09/26/2025

Oncology

FDA Approval

FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

09/25/2025

Stephanie Holland

The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.

The FDA has approved...

09/25/2025

Oncology

News

Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors

09/25/2025

Allison Casey

Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.

Pexidartinib showed sustained...

09/25/2025

Oncology

News

Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma

09/24/2025

Emily Estrada

For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.

For patients with...

09/24/2025

Oncology

News

First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer

09/23/2025

Stephanie Holland

Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...

Results from the phase 2/3...

09/23/2025

Oncology

News

Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor

09/23/2025

Allison Casey

According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.

According to a phase 2a trial,...

09/23/2025

Oncology

News

Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor

09/23/2025

Allison Casey

According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.

According to an analysis of the...

09/23/2025

Oncology

News

Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer

09/22/2025

Stephanie Holland

According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...

According to results from the...

09/22/2025

Oncology